Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
This article was originally published in Scrip
Executive Summary
Pfizer Inc. CEO Ian Read said the company is evaluating tax inversion M&A opportunities but noted the big pharma would need to complete such a deal by the end of 2016, after which a new Congress would be in place – presenting further regulatory risks.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.